Why does the Octaplasma Product Monograph recommend avoiding concomitant administration of other blood products?
Concomitant administration of other blood products with plasma is a common and accepted clinical practice. Patients with multiple intravenous lines could receive blood products simultaneously as happens in trauma settings. We also know from the PROPPR trial that blood products administered within minutes of arrival using a transfusion ratio of 1:1:1 was associated with more patients achieving hemostasis and decreased hemorrhage-related deaths over the first 24 hours.
Octaplasma should NOT be mixed with other drugs/medicinal products and solutions, as inactivation and precipitation may occur. For instance, Octaplasma must not come in direct contact with calcium-containing solutions as calcium promotes clot formation by reacting with the citrate present in Octaplasma as an anticoagulant agent.
